EW Chart

1 Month

	Date	Diff
	2023-12-07	-1.77 %
In a tax-free spinoff transaction, Edwards Lifesciences plans to create an independent company out of its critical-care unit, which is expected to generate approximately $905 million in revenue; the decline in the company's stock may be attributed to this announcement. Edwards Lifesciences (EW) plans to spin off its critical-care unit into an independent company by the end of 2024, which is expected to generate $905 million in sales in 2023; the stock went down due to a slowdown in the economy and lackluster M&A activity.
	2023-12-06	+0.93 %
The article reports that Edwards Lifesciences (EW) stock experienced a slight increase of 0.93% and attributes this to positive financial indicators, such as a strong market capitalization, solid revenue growth, and investor confidence in its earnings capacity.
	2023-12-04	+1.2 %
Edwards Lifesciences Corp. (EW) stock went up by 1.2% despite a poor trading session for the overall stock market. The company outperformed some of its competitors, including Abbott Laboratories, Medtronic PLC, and Stryker Corp. The stock's increase in value was its fourth consecutive day of gains. The reason for the stock's increase is not mentioned in the article.
	2023-12-01	+0.96 %
Shares of Edwards Lifesciences Corp. (EW) increased by 0.96% due to a favorable trading session in the stock market, with the S&P 500 and Dow Jones Industrial Average also rising, and it outperformed some of its competitors.
	2023-11-28	-0.09 %
Shares of Edwards Lifesciences (EW) fell 0.09% on Tuesday, marking the stock's second consecutive day of losses. The reason for the decline is not mentioned in the article. Edwards Lifesciences (EW) stock was down 0.09% and was cut to Underperform by Wolfe Research due to concern over the risk of US Transcatheter Aortic Valve Replacement (TAVR) disappointment as competition in the market rises in the coming years.
	2023-11-22	+0.15 %
Shares of Edwards Lifesciences (EW) increased by 0.15% on Wednesday, following a positive trading session for the overall stock market, with the S&P 500 and Dow Jones Industrial Average also rising. The reason for the increase in EW stock is not mentioned in the article.
	2023-11-06	+0.04 %
Shares of Edwards Lifesciences Corp. (EW) increased by 0.04% on Monday, marking the stock's sixth consecutive day of gains, amid a generally favorable trading session for the stock market. The rise in EW stock can be attributed to the overall positive performance of the S&P 500 Index and the Dow Jones Industrial Average.
	2023-11-01	+0.17 %
The article discusses the performance of Edwards Lifesciences (EW) stock, which saw a slight increase of 0.17% last night. The reason for the stock's increase is not mentioned in the article. Shares of Edwards Lifesciences (EW) went up by 0.17% due to a positive trading session in the stock market, with the S&P 500 and Dow Jones Industrial Average also rising.
	2023-10-26	-8.14 %
The article announces that Edwards Lifesciences (EW) has released positive results from its TRISCEND II trial on the safety and effectiveness of the EVOQUE tricuspid valve replacement system, but it does not explain why the stock went down. Edwards Lifesciences (EW) stock went down by 8.14% due to the release of one-year results from the CLASP IID trial, which confirmed the safety and efficacy of the PASCAL system for degenerative mitral regurgitation. The article discusses how Edwards Lifesciences (EW) stock went down by -8.14% last night. The reason for the stock decline is not mentioned in the article.
	2023-10-24	+2.09 %
Edwards Lifesciences (EW) stock went up 2.09% after the company announced new data from the PARTNER 3 trial showing low rates of mortality, stroke, and rehospitalization in patients who received the SAPIEN 3 valve, reaffirming its clinical outcome benefits and durability. Shares of Edwards Lifesciences Corp. (EW) rose 2.09% due to a positive trading session in the stock market, with the S&P 500 Index and Dow Jones Industrial Average also rising. The stock outperformed some of its competitors, including Abbott Laboratories, Medtronic PLC, and Stryker Corp. Trading volume was higher than the 50-day average volume.
	2023-10-18	-0.88 %
The article announces that Edwards Lifesciences will be hosting an earnings conference call on October 25, 2023 to discuss their operating results for the quarter ended September 30, 2023, and provides information on how to participate in the call. The article does not mention why the stock went down.
	2023-10-12	-1.71 %
Edwards Lifesciences (EW) stock went down by 1.71% due to a rough trading session in the overall stock market, with the S&P 500 and Dow Jones Industrial Average also falling.
	2023-09-28	-0.21 %
The article discusses the H1 2023 financial results of Affluent Medical, a French clinical-stage MedTech company specializing in innovative medical prostheses, and provides updates on its clinical programs. Edwards Lifesciences (EW) stock went down because it is one of Affluent Medical's commercial partners and the Company announced a strategic shift towards the US market, which may impact their partnership. The article discusses the H1 2023 financial results for Affluent Medical, a French clinical-stage MedTech company specializing in medical prostheses, and provides updates on its clinical programs. The stock of Edwards Lifesciences (EW) went down by -0.21% for reasons unrelated to the article.
	2023-09-27	-0.37 %
Shares of Edwards Lifesciences Corp (EW) went down by 0.37% to $70.11 on a mixed trading session for the stock market, with the Dow Jones Industrial Average falling by 0.20% and the S&P 500 Index rising by 0.02%; the reason for the decline in EW stock is not mentioned in the article. The article states that Edwards Lifesciences (EW) stock went down by -0.37% last night, but does not provide a specific reason for the decline.
	2023-09-26	+1.31 %
Oppenheimer analyst raised Edwards Lifesciences (EW) stock to Outperform with a $90 price target, citing the company's Transcatheter Tricuspid as an exciting opportunity and the stock's attractive risk-reward profile. However, there was negative news as the company was raided by EU antitrust regulators. The article states that the stock of Edwards Lifesciences (EW) went up by 1.31% last night, but does not provide a definitive reason for the increase. Edwards Lifesciences (EW) stock went up by 1.31% following a raid by EU antitrust regulators at one of its EU facilities, indicating that investors are not significantly worried about the potential market power abuse investigation.
	2023-09-21	-2.46 %
The article analyzes Edwards Lifesciences' use of debt and its impact on the company's risk. While Edwards Lifesciences has a net cash position and solid balance sheet, its declining earnings and ability to convert earnings to free cash flow could make managing debt more challenging. The article suggests that the recent decline in the company's stock price may be due to concerns about its liabilities.
	2023-09-20	-1.47 %
The article does not provide any information about why Edwards Lifesciences (EW) stock went down -1.47% last night. The article discusses the recent decline in the stock price of Edwards Lifesciences (EW) and explores the possibility that the stock may be undervalued. The decline in the stock price could be attributed to various factors, but the article highlights the company's strong financial condition, profitability, and growth potential as reasons why the stock may be undervalued. The article discusses Edwards Lifesciences Corp's stock performance, which recently experienced a 1.47% drop. The reason for the decline is not specified in the article. However, the article highlights the company's robust financial stance, citing its high rankings in financial strength, profitability, and growth. The GuruFocus Score Rating, which measures the company's performance, gives Edwards Lifesciences Corp a score of 97 out of 100, indicating high potential for outperformance. Overall, the article suggests that the company is well-positioned for future growth and stability.
	2023-09-15	-1.11 %
The article discusses the recent sale of 4,500 shares of Edwards Lifesciences Corp (EW) by an insider, which has raised questions about the company's stock performance and its relationship with insider trading activities. The stock has been consistently sold by insiders over the past year, but the company's undervalued status based on its GF Value suggests potential for growth. The reason for the stock going down is not explicitly stated in the article.
	2023-09-14	+1.16 %
The article discusses how Edwards Lifesciences (EW) stock went up 1.16% and Jim Cramer comments on the company, stating that it used to be a great stock but now it is performing poorly. The reason behind the stock going up is not mentioned in the article.
	2023-09-13	-0.27 %
Edwards Lifesciences' stock has declined 19% in the past three months, but its strong financials suggest that the stock could potentially see long-term value increase, as the company has a high return on equity (ROE) of 22% and has seen substantial earnings growth as it reinvests profits back into the business. The stock's recent downturn may be influenced by analyst predictions of a slowdown in future earnings growth. Edwards Lifesciences (EW) stock went down 0.27% as part of a mixed trading session in the stock market, where the S&P 500 Index rose 0.12% and the Dow Jones Industrial Average fell 0.20%.
	2023-09-12	-2 %
In a recent article, Jim Cramer discusses the decline of Edwards Lifesciences (EW) stock, calling it "terrible" and expressing uncertainty about its future performance. The reason for the stock's decline is not explicitly stated in the article. Edwards Lifesciences (EW) stock fell 2.00% due to a general downturn in the stock market, with the S&P 500 and Dow Jones Industrial Average also experiencing decreases. The stock underperformed compared to its competitors, including Abbott Laboratories, Medtronic PLC, and Stryker Corp. The trading volume was lower than the 50-day average volume.
	2023-09-11	+1.08 %
Edwards Lifesciences Corp. (EW) stock increased by 1.08% on a favorable trading day for the market, although it underperformed compared to some of its competitors such as Abbott Laboratories, Medtronic PLC, and Stryker Corp. The recent weakness in the U.S. stock market is likely to continue in the near-term.
	2023-09-08	-2.65 %
The article discusses the performance of Edwards Lifesciences (EW) stock, which fell 2.65% in the last trading session. The reason for the decline is not mentioned in the article.
	2023-09-07	-1.13 %
The article discusses the performance of GE HealthCare Technologies Inc., which recently had a secondary offering and saw its stock slide 14%. Despite this, Wall Street sees it as an opportunity due to the company's growth potential and positive analyst sentiment. Edwards Lifesciences (EW) stock went down due to a secondary offering by GE HealthCare Technologies Inc, which led to a decline in its stock price.
	2023-09-06	+1.3 %
The article highlights the strong financial stance of Edwards Lifesciences Corp (EW) and suggests that the company is well-positioned for substantial growth in the near future. The stock went up by 1.3% last night. The reasons for the stock's increase are not explicitly mentioned in the article.
	2023-09-05	-0.54 %
The article announces key updates to Zimmer Biomet Holdings' Executive Leadership Team, including the promotion of Wilfred van Zuilen to Group President, EMEA; the promotion of Mark Bezjak to President of the Americas; and the appointment of Nitin Goyal, M.D. to the Executive Leadership Team. The stock of Edwards Lifesciences (EW) has gone down, but the article does not provide any information about why this has happened.
	2023-09-01	-0.12 %
The article discusses the financial metrics of Edwards Lifesciences (EW) and highlights its growing return on capital employed (ROCE) and increased capital deployment. The company has an ROCE of 21%, which is higher than the industry average of 9.2%. The article suggests that these strong fundamentals make the stock worth further research, despite its higher price. The author believes that Edwards Lifesciences has the potential to be a multi-bagger, and shareholders have already earned a respectable 63% return over the past five years. However, the article does not provide a specific reason for the recent -0.12% decrease in the stock price.
	2023-08-31	-1.73 %
Edwards Lifesciences' stock went down by -1.73% last night, and the reason for the decline is not mentioned in the article.
	2023-08-29	+2.37 %
The article announces that Edwards Lifesciences Corp. (EW) has been named as the "Stock to Study" by the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine, and states that a company's fundamentals, such as earnings, are the key driving force behind its stock price appreciation. The article does not provide information on why Edwards Lifesciences' stock went up. Edwards Lifesciences (EW) stock went up 2.37% last night, and it has the potential for future gains once concerns about a potential recession subside, despite slower-than-expected sales growth for its transcatheter aortic valve replacement business. The company's stock is currently trading at a lower valuation multiple compared to pre-pandemic levels, but there is still potential upside due to its strong fundamentals and cash position. In the November 2023 issue of BetterInvesting Magazine, Edwards Lifesciences Corp. (EW) is announced as the "Stock to Study." The stock went up 2.37% last night, and the reason behind the increase is not mentioned in the article.
	2023-08-28	-0.18 %
The article explains that the decline in Edwards Lifesciences (EW) stock may be influenced by the substantial holdings of institutions, which can have significant influence over the company's share price. Insider selling has also been noted. The article announces that Edwards Lifesciences is scheduled to present at the 2023 Wells Fargo Healthcare Conference, and provides information on the speakers and where to access the presentation. The reason for the stock going down is not mentioned in the article.
	2023-08-18	-0.33 %
The article discusses the use of debt by Edwards Lifesciences (EW) and whether shareholders should be concerned. The company has a significant amount of cash to offset its debt and its balance sheet looks quite solid. However, the company saw a decline in earnings over the past year, which could make it more difficult for them to manage their debt. Overall, the article concludes that while it is always important to consider a company's liabilities, Edwards Lifesciences' use of debt does not appear to be risky. The reason for the recent decline in EW stock is not mentioned in the article.
	2023-08-17	-2.49 %
The article discusses the recent drop in Edwards Lifesciences (EW) stock and attributes it to the opinions of 12 Wall Street analysts who have an average price target of $101.5 for the company.
	2023-08-14	+1.41 %
The article discusses the recent drop in Edwards Lifesciences Corporation (EW) stock price, but highlights that the stock has performed well over the past five years with a 69% increase. The article suggests that the market may be becoming more cautious towards the stock, as the compound earnings per share (EPS) growth of 17% per year is more impressive than the 11% yearly share price gain. The article also mentions the CEO's lower pay compared to similar companies and suggests that long-term investors may see the current sell-off as an opportunity, especially if the fundamental data indicates long-term sustainable growth.
	2023-08-08	-1.57 %
The stock of Edwards Lifesciences Corp. (EW) went down by 1.57%. The overall stock market also had a dismal trading session, with the S&P 500 Index and Dow Jones Industrial Average both falling. The reason for the decline in EW stock is not mentioned in the article.
	2023-08-01	-0.02 %
The article discusses the current valuation of Edwards Lifesciences Corporation (EW) stock, stating that it is currently overvalued by about 31% compared to its intrinsic value. This may be a reason why the stock has gone down by -0.02%. The article suggests that investors should keep an eye out for a potential price decline in order to buy at a lower price. Additionally, the future outlook for Edwards Lifesciences appears positive, with profit expected to grow by 38% in the next few years. However, the article also warns that the stock may have already factored in this optimistic growth, indicating that it may be overpriced at the moment. Overall, investors may want to wait for a potential price drop before considering buying or selling the stock.
	2023-07-27	-9.78 %
Edwards Lifesciences (EW) stock went down by 9.8% after the company's guidance for the third quarter fell short of Wall Street analysts' expectations.
	2023-07-24	-1.26 %
Edwards Lifesciences (EW) stock was down 1.26% last night, possibly due to the market's assessment of the company's long-term financial health and its return on equity (ROE). Despite having a significantly high ROE compared to the industry average, the stock's future earnings growth is expected to slow down. Additionally, the company does not pay dividends and reinvests all its profits into the business.
	2023-07-20	+1.12 %
The article mentions that Edwards Lifesciences (EW) stock went up by 1.12% last night, but it does not explain why the stock price increased.
	2023-07-19	-0.4 %
The article announces that Edwards Lifesciences plans to announce its operating results for the quarter ended June 30, 2023, and host a conference call to discuss those results; however, it does not provide any information on why the stock went down.
	2023-07-03	-3.01 %
The article discusses Edwards Lifesciences Corporation (EW) and its debt levels. While the company does carry debt, it also has a significant amount of cash to offset it. The balance sheet appears solid, and the company has been able to increase its earnings before interest and tax (EBIT) over the past year. Overall, the article suggests that the debt is not a major risk for Edwards Lifesciences. The reason for the 3.01% drop in the stock price is not mentioned in the article.
	2023-06-30	+2.51 %
The article briefly mentions that the stock of Edwards Lifesciences (EW) rose by 2.51% and attributes this increase to a favorable trading session for the stock market in general.
	2023-06-27	+0.78 %
The article discusses how AI can revolutionize medical technology by addressing inefficiencies in medical workflows and offers various examples, such as Edwards Lifesciences' HemoSphere laying AI capabilities on top of their new Acumen product to predict potential issues, which could explain why Edwards Lifesciences (EW) stock went up.
	2023-06-14	+3.58 %
Edwards Lifesciences (EW) stock went up by 3.6% last night after it was highlighted that consumers are getting knee procedures and other outpatient services done, which could raise costs for insurers leading to insurers like UnitedHealth Group dropping 6.4% and Humana falling 11.2%. The Edwards Lifesciences (EW) stock went up by 3.58% after UnitedHealth Group's warning about rising costs as surgeries for senior citizens boosted the medical device maker's shares.
	2023-06-13	+2.14 %
Edwards Lifesciences (EW) stock rose 2.14% on Tuesday, its fourth consecutive day of gains, and outperformed its healthcare competitors as trading volume eclipsed its 50-day average volume of 2.6 million, but there was no specific reason given for the rise in the stock.
	2023-06-12	+1.75 %
Shares of Edwards Lifesciences (EW) rose 1.75% on Monday, outperforming some of its competitors, such as Stryker Corp., Medtronic PLC, and Intuitive Surgical Inc., due to reasons that are not specified in the article.